- Home
- LPRO vs ALMS Comparison
LPRO vs ALMS Comparison
Compare LPRO & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- ALMS
- Stock Information
- Founded
- LPRO 2000
- ALMS 2021
- Country
- LPRO United States
- ALMS United States
- Employees
- LPRO N/A
- ALMS N/A
- Industry
- LPRO Finance: Consumer Services
- ALMS
- Sector
- LPRO Finance
- ALMS
- Exchange
- LPRO Nasdaq
- ALMS NYSE
- Market Cap
- LPRO 751.9M
- ALMS 652.3M
- IPO Year
- LPRO N/A
- ALMS 2024
- Fundamental
- Price
- LPRO $6.27
- ALMS $8.85
- Analyst Decision
- LPRO Buy
- ALMS Strong Buy
- Analyst Count
- LPRO 7
- ALMS 6
- Target Price
- LPRO $6.80
- ALMS $29.60
- AVG Volume (30 Days)
- LPRO 427.7K
- ALMS 78.8K
- Earning Date
- LPRO 11-07-2024
- ALMS 11-13-2024
- Dividend Yield
- LPRO N/A
- ALMS N/A
- EPS Growth
- LPRO N/A
- ALMS N/A
- EPS
- LPRO 0.04
- ALMS N/A
- Revenue
- LPRO $95,887,000.00
- ALMS N/A
- Revenue This Year
- LPRO N/A
- ALMS N/A
- Revenue Next Year
- LPRO $15.00
- ALMS N/A
- P/E Ratio
- LPRO $164.12
- ALMS N/A
- Revenue Growth
- LPRO N/A
- ALMS N/A
- 52 Week Low
- LPRO $4.57
- ALMS $8.23
- 52 Week High
- LPRO $8.70
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- LPRO 54.27
- ALMS N/A
- Support Level
- LPRO $6.13
- ALMS N/A
- Resistance Level
- LPRO $6.80
- ALMS N/A
- Average True Range (ATR)
- LPRO 0.37
- ALMS 0.00
- MACD
- LPRO 0.04
- ALMS 0.00
- Stochastic Oscillator
- LPRO 60.12
- ALMS 0.00
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against losses from defaults.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.